temozolomide

Adult Dosing .

Dosage forms:  CAP: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, prophylactic meds, and dosing incl. toxicity-related dose adjustments

glioblastoma, newly diagnosed

[concomitant focal XRT phase]

Dose: 75 mg/m^2/dose PO qd x42-49 days; Info: PCP prophylaxis required; do not open/crush/chew cap

[maintenance phase]

Dose: 150 mg/m^2/dose PO qd on days 1-5 of 28-day cycle x6 cycles; Start: 4wk after completing concomitant focal XRT phase; Info: may incr. dose to 200 mg/m^2/dose for cycles 2-6 if no dose interruption or D/C d/t toxicity in cycle 1; cont. PCP prophylaxis if lymphopenia >Grade 1; do not open/crush/chew cap

anaplastic astrocytoma

[adjuvant tx, newly diagnosed dz]

Dose: 150 mg/m^2/dose PO qd on days 1-5 of 28-day cycle x12 cycles; Start: 4wk after completing XRT; Info: incr. dose to 200 mg/m^2/dose for cycles 2-12 if no/minimal toxicity in cycle 1; do not open/crush/chew cap

[refractory dz]

Dose: 150 mg/m^2/dose PO qd on days 1-5 of 28-day cycle; Info: incr. dose to 200 mg/m^2/dose starting cycle 2 if ANC>1500 and Plt >100,000 at nadir and on day 1 of cycle; do not open/crush/chew cap

malignant melanoma (off-label)

[monotherapy]

Dose: 150-200 mg/m^2/dose PO qd on days 1-5 of 28-day cycle; Info: do not open/crush/chew cap

[combo tx]

Dose: 150 mg/m^2/dose PO qd on days 1-4 of 21-day cycle; Info: do not open/crush/chew cap

renal dosing

[see below]

CrCl >36: no adjustment; CrCl <36: not defined

HD/PD: not defined

hepatic dosing

[see below]

Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.